25 completed, 4 unknown, 3 recruiting. 32 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Completed 25, Unknown 4, Recruiting 3 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
| Phase 3 | 2 | Completed 2 |
Follow Hyperphosphatemia: new trials by email Literature Review of Hyperphosphatemia trials Research Report on Hyperphosphatemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phosphate in Acute Pancreatitis Sodium Phosphate, Potassium Phosphate - Pancreatitis | Phase 2 | Recruiting | Duke University | 100 | 2026-07-09 | 2026-08-26 |
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 2 | Recruiting | R1 Therapeutics | 168 | 2026-06-01 | 2026-08-26 |
| Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia JMKX003002 will be administered orally, Sevelamer carbonate - Hyperphosphatemia | Phase 2 | Recruiting | Jemincare | 50 | 2024-12-30 | 2025-02-03 |
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | Grand Life Science (Liaoning) Co., Ltd. | 48 | 2020-10-21 | 2021-07-28 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients VS-505, Sevelamer Carbonate - Hyperphosphatemia | Phase 2 | Completed | Shanghai Alebund Pharmaceuticals Limited | 158 | 2020-10-13 | 2022-10-18 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebp - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 47 | 2019-04-29 | 2024-03-07 |
| Dose-finding Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebo - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 207 | 2019-04-15 | 2024-03-07 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD KHK7791 - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 67 | 2018-12-27 | 2024-03-07 |
| A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis VS-505 - End Stage Renal Disease, Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | KDL Inc. | 30 | 2015-06-01 | 2016-02-08 |
| Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease PT20, Placebo - Hyperphosphataemia | Phase 2 | Completed | Phosphate Therapeutics | 153 | 2014-05-07 | 2018-01-16 |
| Dose Finding Study to Treat High Phosphate Levels in the Blood. AZD1722, Placebo - Hyperphosphatemia | Phase 2 | Completed | Ardelyx | 162 | 2014-03-01 | 2020-09-14 |
| Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Osvaren Granules, Osvaren film-coated tablets - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Fresenius Medical Care Deutschland GmbH | 61 | 2014-01-01 | 2015-06-10 |
| A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis Lanthanum Carbonate, Calcium Carbonate - Chronic Kidney Disease, Hyperphosphatemia | Phase 2 | Completed | Shire | 63 | 2013-02-15 | 2021-06-10 |
| An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease Placebo, Sevelamer carbonate - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | Genzyme, a Sanofi Company | 101 | 2012-05-01 | 2016-07-25 |
| PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia PA21, Placebo - Chronic Kidney Disease Requiring Hemodialysis | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 183 | 2012-01-11 | 2018-08-23 |
| Nicotinamide in Hemodialysis Patients With Hyperphosphatemia Nicotinamide - Chronic Kidney Disease, Hemodialysis | Phase 2 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | 252 | 2010-08-01 | 2012-01-18 |
| A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia HS219, Placebo - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | KDL Inc. | 68 | 2009-12-01 | 2015-09-14 |
| Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis Placebo, Genz-644470, Sevelamer carbonate - Kidney Failure, Chronic | Phase 2 | Completed | Genzyme, a Sanofi Company | 349 | 2009-02-01 | 2015-05-01 |
Showing 20 of 32. Sign in to see all of them.
Renal Insufficiency, Chronic (11) · Kidney Failure, Chronic (8) · Kidney Diseases (3) · Renal Insufficiency (2) · Bronchiolitis Obliterans Syndrome (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Hypophosphatemia (1) · Inflammation (1) · Pancreatitis (1)
Metabolic Diseases (32) · Nutritional and Metabolic Diseases (32) · Phosphorus Metabolism Disorders (32) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Male Urogenital Diseases (19) · Urogenital Diseases (19) · Urologic Diseases (19) · Chronic Disease (18) · Disease Attributes (18) · Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Kidney Diseases (16) · Renal Insufficiency (16) · Renal Insufficiency, Chronic (7)
Sevelamer (10) · lanthanum carbonate (4) · tenapanor (3) · Calcium Carbonate (2) · Niacinamide (2) · SBR 759 (2) · ferric citrate (2) · iron-magnesium hydroxycarbonate (2) · BID protein, human (1) · Geritol (1) · Iron (1) · calcium acetate (1) · potassium phosphate (1) · sodium phosphate (1) · sucroferric oxyhydroxide (1)
Kyowa Kirin Co., Ltd. (3) · Ardelyx (2) · Bayer (2) · Genzyme, a Sanofi Company (2) · Ineos Healthcare Limited (2) · KDL Inc. (2) · Novartis Pharmaceuticals (2) · Alebund Pharmaceuticals (1) · Astellas Pharma Inc (1) · Duke University (1) · Fresenius Medical Care Deutschland GmbH (1) · Grand Life Science (Liaoning) Co., Ltd. (1) · Ilypsa (1) · Jemincare (1) · Keryx Biopharmaceuticals (1)
United States (13) · Japan (9) · China (5) · Germany (5) · United Kingdom (4) · Poland (3) · Australia (2) · France (2) · Puerto Rico (2) · Argentina (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · Finland (1)
Alan H Lau, Pharm.D. (1) · Daniel O Young, MD (1) · David P Rosenbaum, PhD (1) · Geoff Block, MD (1) · Geoffrey A Block, MD (1) · Guido Smeets, MD (1) · Johan Rosman, MD, Ph.D (1) · Julia B Lewis, MD (1) · Li Wang, MD (1) · Maarten Taal, MBChB MD FRCP (1) · Masafumi Fukagawa, MD, PhD (1)
PMID 40576086, PMID 21854503, PMID 38323855, PMID 19776051, PMID 21426511, PMID 24968790, PMID 24975892, PMID 29617976, PMID 32651955, PMID 33766811, PMID 35236302, PMID 38453435
2009 (1), R01DK142980 (1)